Exhibit 99.1

Simulations Plus, Inc.

(NASDAQ:SLP)

Fourth Quarter and Fiscal Year 2011

Conference Call and Webinar

December 1, 2011

With the exception of historical information, the matters discussed in this
presentation are forward-looking statements that involve a number of risks
and uncertainties. The actual results of the Company could differ
significantly from those statements. Factors that could cause or contribute
to such differences include, but are not limited to: continuing demand for
the Company’s products, competitive factors, the Company’s ability to
finance future growth, the Company’s ability to produce and market new
products in a timely fashion, the Company’s ability to continue to attract
and retain skilled personnel, and the Company’s ability to sustain or
improve current levels of productivity. Further information on the
Company’s risk factors is contained in the Company’s quarterly and
annual reports and filed with the Securities and Exchange Commission.

Safe Harbor Statement

•4Q11 compared to 4Q10:

–16th consecutive profitable quarter(38 of last 40 were profitable)

–4Q11 sales lower 3.9% to $2.12 million from $2.21 million

–Words+ subsidiary sales down 20.5%

–Net Income down 46.3% to $0.186 million from $0.345 million

–Diluted earnings per share down 44.4% to $0.01 from $0.02

•FY11 compared to FY10:

–Sales up 9.4% to Record $11.72 MM from $10.71 MM in FY10

–Words+ subsidiary sales down 3.6% to $2.98 million from $3.09 million

–Net Income up 25.9% to $2.71 million from $2.16 million

–Diluted earnings per share up 29.3% to $0.17 from $0.13

•Strong balance sheet:

–Cash $10.2 MM at 8/31/11, after using $2.07 million cash to repurchase shares
during FY11. (Cash today = $12.3 millionafter closing sale of Words+ yesterday)

–Shareholders’ equity up 7.6% to $14.0 million from $13.0 million at 9/1/10

–Equity per share up 9.4% to $0.90 from $0.82 at 9/1/10

–No debt

SLP 4Q11 Highlights
Three months and fiscal year ended 8/31/11

Consolidated Revenue

Revenue History by Division

Gross Margin (consolidated)

75.6%

78.9%

78.8%

70.4%

73.8%

74.4%

80.0%

67.9%

75.0%

76.3%

77.6%

75.6%

73.6%

77.6%

76.3%

73.0%

Income Before Taxes (consolidated)

Net Income by Division

$243K

$565K

$764K

$165K

$312K

$368K

$569K

$163K

$430K

$641K

$740K

$345K

$567K

$907K

$1.054 M

$185K

Consolidated Income Statement 4QFY11 vs 4QFY10

($ millions)

	4Q11	4Q10
Pharmaceutical software and services revenue	1.427	1.334
Words+ revenue	0.693	0.872
Consolidated revenue	2.120	2.206
Gross profit	1.547	1.667
Gross profit margin	73.0%	75.6%
SG&A	1.199	1.115
R&D	0.234	0.222
Total operating expenses	1.433	1.337
Income before income taxes	0.172	0.357
Net income	0.185	0.345
Earnings per share (diluted)	0.012	0.022

Selected Balance Sheet Items

($ millions)

	August 31, 2011	August 31, 2010
Cash and cash equivalents	$10.181	$9.631
Total current assets	13.275	12.390
Total assets	$15.867	$14.660
Total current liabilities	1.141	1.204
Total liabilities	1.830	1.615
Shareholders’ equity	14.036	13.045
Total liabilities and shareholders’ equity	15.867	14.660

•The sale of our Words+ subsidiary was closed on November
30, 2011

•Proceeds after adjusting for changes in Net Working Capital
from August 31, 2011 were $1.98 million

•This sale is expected to have the following effects:

–Reduce our employee count to 24 from 39

–Reduce our auditing and legal fees going forward

–Simplify our accounting and reporting

–Simplify our internal controls (no hardware inventory, etc.)

–Reduce our revenues by ~$3MM/year

–Increase in office space available at increased lease cost

–Stronger balance sheet - increased cash and decreased total
liabilities (accrued vacations for Words+ employees paid off)

–Increase our profit margin and net earnings

–Focus our energies and resources on growing the pharmaceutical
software and services business

Sale of Words+ Subsidiary

•Going forward, Words+ will be reported as “discontinued
operations”

•The next slides show the past financial performance of
the pharmaceutical software and services business by
itself to provide an indication of how the business will be
reported from now on

•Adjustments to these numbers for changes in various
expenses will be provided in pro forma financials to be
included in an 8K filing in the next 3 working days

–Lease costs will be going up

–Sublease income will be generated and treated as other income

•This will eventually be decreased as some Words+ operations move to Ohio

•It may go away completely at some point if PRC moves remaining operations

–Insurance and other overhead costs are expected to decrease

–Auditing and legal costs are expected to decrease

Sale of Words+ Subsidiary

Pharmaceutical Software &
Services Revenues by Fiscal Year

Pharmaceutical Software &
Services Net Income by Quarter

Pharmaceutical Software & Services
Net Income by Fiscal Year

Marketing and Sales Program

•Conferences/Scientific Meetings

•Training Workshops

•Posters, Presentations, and Peer-Reviewed Publications

•Strategic Digital Marketing Initiatives

•Collaborations/Consulting/Grants

–Progressing on our 5-year collaboration with the FDA Center for Food
Safety and Applied Nutrition to build toxicity models with ADMET
Predictor/Modeler™ for food additives and contaminants

–Consulting studies for both large and small companies (4 active projects)

–Negotiating a new funded collaboration with a top 5 pharmaceutical
company to further enhance our GastroPlus software product

•Fundamental industry shift continues

–Pharma increasingly utilizing simulation software and modeling tools to
increase productivity - steady stream of scientific meetings

–Recent AAPS meeting had 20+ presentations referencing our
software - several from the FDA

–Software tools are always evolving, and as the technology advances,

new capabilities attract new users

–58 new customers during FY11 (includes new companies and new
departments within existing large customers)

•Simulations Plus continues to increase its technological advantage

Ongoing Enhancements

•Version 8.0 release expected in December 2011 - major upgrade

•Expanded drug-drug interaction to include transporters and induction

•Expanded PDPlus™ pharmacodynamics modeling module

•Expanded ocular delivery model

•Expanded nasal/pulmonary delivery model

•Version 6.0 release expected in December 2011 - major upgrade

•Prediction of sites of metabolism now available

•Best-in-class pKa models improved and display enhanced

•Retrained models with new atomic level descriptors -our already top-ranked
property predictions were further improved

•Version 2.0 was released in April - major upgrade

•Integration of new MedChem Designer software

•MedChem Designer downloads/activations over 1600

•Significant improvements in processing speed

•Prediction of metabolite structures to be available soon

•Version 4.0 released in June

•Virtual Trials added to show expected variances in experiments

•FDA added more licenses during 3rd quarter

•Customer base continues to grow

Summary

•For FY11:

•Revenues = $11.8 million (up9.4%)

•Net Income = $2.71 million (up25.9%)

•Earnings/share = $0.17 (up29.3%)

•Cash = $10.2 million (up 5.7% after share repurchases of $2.07)

•Continuing to Expand our Life Sciences team:

•To promote faster development of new products and services

•To strengthen our marketing and sales efforts

•Simulations Plus is globally recognized as a leader in our
respective market niches

•Outstanding reputation for scientific expertise and innovation

•Strong customer support

•Sale of Words+ strengthens Simulations Plus

•Additional cash and reduced liabilities will strengthen balance sheet

•Will allow focusing our energies and resources on the pharmaceutical software
and services business

Q&A